20 years of biosimilars: Are we on the right track?

In a recent panel discussion hosted by PharmaLex, industry experts discussed biosimilars’ progress since their introduction some 20 years ago, what’s on the horizon, the regulatory climate, and strategies to increase biosimilar uptake. Due to the demand for information surrounding biosimilars, the panel discussion was captured as a white paper, and is now available for download.

Register To Download

**For more information, please see Cencora PharmaLex Privacy Policy. If you do not wish to receive any communication from us, you may unsubscribe at any time.

With the worldwide market for biosimilars valued at USD 35 million in 2022 and poised to more than double by 2030 to $74 billion,* it’s clear that the industry is betting on the promise of biosimilars. As much promise as there may be in how biosimilars can offer more comparable treatments at reduced costs, there is also great debate.

Key learning objectives:

  • The current state of the biosimilars market
  • Shifts in stakeholder acceptance
  • Market opportunities by originator companies
  • Challenges and barriers that remain
  • Experts’ predications on what’s to come
Download The free eBook